Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-JNJ-39823277 · 1 trial · 1 indication
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
The AUClast is area under the plasma concentration-time curve from time zero to the last quantifiable concentration.
The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of Area under Curve (AUC) last and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.
T1/2 is the time measured for the plasma concentration to decrease by one-half of its original concentration. It is associated with the terminal rate-constant (lambda\[z\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
| Arm | Type | Description |
|---|---|---|
| 14C-JNJ-39823277 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 14C-JNJ-39823277 | DRUG | Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution. |
Inclusion Criteria: * Body mass index (BMI) between 20 and 30 kg/m2 (BMI will be calculated as weight \[kg\]/square of height \[square meter\]) * Had consistent bowel movement habit (approximately once per day) within 30 days before dosing * No clinically significant laboratory and electrocardiogra...
14C-JNJ-39823277 is an investigational small molecule being developed by Johnson & Johnson (JNJ). It is currently in Phase 1 clinical development. The drug is being studied in healthy male participants to evaluate its absorption, metabolism, and excretion. It is not approved and remains in clinical trials.
14C-JNJ-39823277 is being studied in healthy volunteers to evaluate its absorption, metabolism, and excretion. It is an investigational small molecule in Phase 1 clinical development. The study is designed to understand how the drug is processed by the body, which is a standard part of early drug development.
14C-JNJ-39823277 is developed by Johnson & Johnson, a pharmaceutical company traded on the NYSE under the ticker JNJ. The drug is currently in Phase 1 clinical development, with one completed trial in healthy male participants.
14C-JNJ-39823277 is in Phase 1 clinical development. It is an investigational drug and has not been approved. One Phase 1 trial has been completed, which studied the drug in healthy male participants to evaluate its absorption, metabolism, and excretion.
14C-JNJ-39823277 has one completed clinical trial, NCT02049697, titled "A Study to Evaluate of the Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 in Healthy Male Participants." The trial was a Phase 1, uncontrolled study conducted in Belgium with 6 healthy male participants aged 18 years and older.